Novavax, Inc. (NVAX) NASDAQ
7.70
-0.32(-3.99%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
7.70
-0.32(-3.99%)
Currency In USD
Address
21 Firstfield Road
Gaithersburg, MD 20878
United States of America (the)
Phone
240 268 2000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
952
First IPO Date
December 05, 1995
| Name | Title | Pay | Year Born |
| John Charles Jacobs | President, Chief Executive Officer & Director | 1.55M | 1967 |
| James Patrick Kelly | Executive VP, CFO & Treasurer | 880,849 | 1966 |
| Elaine O'Hara | Executive VP & Chief Strategy Officer | 991,316 | 1968 |
| Mark Casey | Executive VP, Chief Legal Officer & Corporate Secretary | 997,654 | 1963 |
| Henrietta Ukwu | Executive VP & Chief Regulatory Officer | 0 | 1967 |
| Ian J. Watkins | Executive VP & Chief Human Resources Officer | 0 | 1963 |
| Richard Crowley | Executive VP & COO | 0 | 1957 |
| Troy Morgan | Senior VP, Deputy General Counsel & Chief Compliance Officer | 0 | 1971 |
| Erika S. Trahan | Associate Director of Investor & Public Relations | 0 | N/A |
| Silvia Taylor | Executive Vice President, Chief Corporate Affairs Officer & Head of Novavax Sweden | 0 | N/A |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.